Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Iruplinalkib trumps crizotinib for ALK TKI-naïve NSCLC
In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).
Iruplinalkib trumps crizotinib for ALK TKI-naïve NSCLC
02 Oct 2023
Pretreatment serum CEA level predicts survival in NSCLC
Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.
Pretreatment serum CEA level predicts survival in NSCLC
29 Sep 2023
Nonerosive GERD patients not prone to develop esophageal adenocarcinoma
Patients with nonerosive gastroesophageal reflux disease (GERD) show no higher incidence of esophageal adenocarcinoma (EAC) when compared with the general population, according to a study.
Nonerosive GERD patients not prone to develop esophageal adenocarcinoma
28 Sep 2023
Atezolizumab-chemo confers durable survival benefit in ES-SCLC
In the merged analysis of the IMpower133 trial and IMbrella A open-label extension study, the combination of the PD-L1 inhibitor atezolizumab and a chemotherapy regimen comprising carboplatin and etoposide (CP/ET) demonstrated potential for survival benefit of up to 5 years in patients with extensive stage-small-cell lung cancer (ES-SCLC).